Aurinia's Lupkynis Shows Sustained Renal Response Rates In Lupus Nephritis Patients

Aurinia Pharmaceuticals Inc AUPH has announced a supportive interim analysis of its AURORA 2 continuation study evaluating Lupkynis (voclosporin) in lupus nephritis.
Data will be presented at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2021 Congress in June.
Subjects who completed one year of treatment in Aurinia's Phase 3 AURORA 1 study were eligible to enroll in the continuation study (AURORA 2).
The interim analysis of AURORA 2 showed that subjects in the Lupkynis treatment arm sustained meaningful reductions in proteinuria, with no change in mean estimated glomerular filtration rate (eGFR) at 104 weeks of treatment.
Proteinuria continued to improve with a greater reduction in UPCR from pre-treatment baseline to year two observed in the voclosporin arm compared to the control arm (-3.1 vs. -2.1 mg/mg).
A greater reduction in proteinuria between arms was observed between 1 and 2 years (1.0 vs. 0.6 mg/mg; voclosporin vs. control).
Renal function as determined by eGFR remained stable over 104 weeks in both groups compared to baseline assessments.
Mean eGFR: 79.6 vs 79.0 mL/min for the voclosporin arm and 78.9 vs 82.9 mL/min for the control arm.
Additionally, there were no unexpected new adverse events observed.
Price Action: AUPH shares closed at $12.82 on Thursday.